Search - tctmd.com

Displaying 281 - 300 of 853

Sort: Relevancy | Date

News Daily News

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

Shelley Wood

January 14, 2020

News Features

The Cancer Patient Needing PCI Poses Conundrums for Care

Shelley Wood

January 14, 2020

News Daily News

New AUC for Cardiac Imaging Follow-up in Congenital Heart Disease

Michael O'Riordan

January 10, 2020

News Daily News

EACTS Offers to Help to Resolve EXCEL Controversy, as CRF Launches Review

Michael O'Riordan

January 08, 2020

News Opinion Conversations in Cardiology

Conversations in Cardiology: In the ISCHEMIA Era, What Role for FFR?

January 02, 2020

News Daily News

EACTS Calls for Independent Left Main CAD Evidence Review, Urges ESC Input

Shelley Wood

December 20, 2019

News Daily News

CvLPRIT: Long-term Reduction in Death/MI With Complete Revascularization

Michael O'Riordan

December 20, 2019

News Opinion Editor's Corner

ISCHEMIA Questions? Some Answers From David Maron

Shelley Wood

December 09, 2019

News Features

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Michael O'Riordan

December 09, 2019

Presentation CACI 2019

Después del COMPLETE Trial, ¿cambió nuestra estrategia de revascularización en el IAM?

Presenter: José A. G. Álvarez

November 29, 2019

News Conference News AHA 2019

Complete Revascularization Benefits May Be Due to Stenting Vulnerable Plaques

Todd Neale

November 21, 2019

News Conference News AHA 2019

ISCHEMIA-CKD: Routine Invasive Approach No Help in CKD Patients With Stable CAD

Todd Neale

November 16, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Opinion Off Script AHA 2019

Off Script: Will ISCHEMIA Answer Our Most Pressing Questions?

Ajay Kirtane, MD, SM

November 12, 2019

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Shelley Wood

November 11, 2019

News Conference News VIVA 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

L.A. McKeown

November 05, 2019

News Daily News

Elderly Women Worse Off Than Men Before and After Acute MI

Yael L. Maxwell

October 22, 2019

News Conference News

Former EXCEL Investigator Alleges Trial Manipulation, Prompting Vehement Denials

Michael O'Riordan

October 07, 2019

News Conference News TCT 2019

FORZA: For Intermediate Lesions, OCT-Guided PCI Costs More, Yields Better Outcomes vs FFR

Caitlin E. Cox

October 01, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

Shelley Wood

October 01, 2019

Advertisement

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

The Cancer Patient Needing PCI Poses Conundrums for Care

New AUC for Cardiac Imaging Follow-up in Congenital Heart Disease

EACTS Offers to Help to Resolve EXCEL Controversy, as CRF Launches Review

Conversations in Cardiology: In the ISCHEMIA Era, What Role for FFR?

EACTS Calls for Independent Left Main CAD Evidence Review, Urges ESC Input

CvLPRIT: Long-term Reduction in Death/MI With Complete Revascularization

ISCHEMIA Questions? Some Answers From David Maron

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Después del COMPLETE Trial, ¿cambió nuestra estrategia de revascularización en el IAM?

Complete Revascularization Benefits May Be Due to Stenting Vulnerable Plaques

ISCHEMIA-CKD: Routine Invasive Approach No Help in CKD Patients With Stable CAD

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Off Script: Will ISCHEMIA Answer Our Most Pressing Questions?

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

Elderly Women Worse Off Than Men Before and After Acute MI

Former EXCEL Investigator Alleges Trial Manipulation, Prompting Vehement Denials

FORZA: For Intermediate Lesions, OCT-Guided PCI Costs More, Yields Better Outcomes vs FFR

TCTMD’s Top 10 Most Popular Stories for September 2019

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content